Skip to content

A case series study on the treatment of IgA nephropathy with Buzhong Qingli method

A case series study on the treatment of IgA nephropathy with Buzhong Qingli method

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000676
Enrollment
Unknown
Registered
2025-04-07
Start date
2024-04-22
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunoglobulin A nephropathy

Interventions

test group:Buzhongqingli decoction (Basic composition: Codonopsis radix 10g Radix astragali 10g Radix scutellaria 15g Bixie 15g Coicis seed 15g
Add flavor: pharyngeal congestion with dandelion 10g forsythe 10g
If loose stool was found more than twice a day 15g white lentil and 15g yam were added. For turbid urine add plantain 15g Shiwei 15g) 1 dose a day each dose decoction 200ml take twice morning and even

Sponsors

Xiyuan Hospital of CACMS
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Renal biopsy confirmed IgA nephropathy; (2) TCM syndrome differentiation conforms to the syndrome of spleen deficiency and damp-heat; (3) age between 18 and 65 years old; (4) CKD stage 1-3 estimated glomerular filtration rate (eGFR)=30ml/min/1.73m2 (calculated by EPI formula); (5) 24-hour urinary protein =2.0g; (6) voluntarily accept this study and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) secondary IgA nephropathy; (2) complicated with serious diseases affecting the survival of patients including serious cardiovascular diseases cerebrovascular diseases malignant tumors hematopoietic system diseases; (3) IgA nephropathy with malignant hypertension and rapid progression and deterioration of renal function; (4) breastfeeding pregnancy or planned pregnancy during the study period; (5) those with mental disorders who cannot receive normal treatment; (6) participating in other clinical investigators; (7) patients with allergy to study drugs or allergic constitution.

Design outcomes

Primary

MeasureTime frame
UA;TCMSS;CREA;24-hour urinary protein quantification;ACR;urine RBC/HPF;BUN;GFR;

Secondary

MeasureTime frame
Triglycerides;Total Cholesterol;Blood Glucose;

Countries

China

Contacts

Public ContactYu Dajun

Xiyuan Hospital of CACMS

yudajunfly@126.com13651229860

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026